Synergistic Effects of Irinotecan and Flavonoids on Ehrlich Ascites Tumour-Bearing Mice

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 5, 2011, Pages 343-349

  Knežević, Anica Horvat ^a   Dikić, Domagoj ^a   Lisičić, Duje ^a   Kopjar, Nevenka ^b   Oršolić, Nada ^a   Karabeg, Sanja ^a   Benković, Vesna ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

AURANTIIN; IRINOTECAN; QUERCETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; EHRLICH ASCITES TUMOR; EHRLICH ASCITES TUMOR CELL; KIDNEY CELL; LEUKOCYTE COUNT; LIFESPAN; LIVER CELL; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, EHRLICH TUMOR; COMET ASSAY; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLAVANONES; HEPATOCYTES; INJECTIONS, INTRAPERITONEAL; KIDNEY; MALE; MICE; PERITONEAL CAVITY; QUERCETIN;

MUS;

EID: 80054087633     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00735.x     Document Type: Article

References (37)

1. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 1998;34:1500-8.
2. Takimoto CH, Wright J, Arbuck SG. Clinical applications of the camptothecins. Biochim Biophys Acta 1998;1400:107-19.
3. Wilkinson K. Irinotecan Hydrochloride. Clin J Oncol Nurs 2001;5:179-81.
4. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002;13:841-51.
5. Oneschuk D, Younus J. Natural health products and cancer chemotherapy and radiation therapy. Oncol Rev 2008;1:233-42.
6. Ng TB, Liu F, Wang ZT. Antioxidative activity of natural products from plants. Life Sci 2000;66:709-23.
7. Rice-Evans C. Flavonoid antioxidants. Curr Med Chem 2001;8:797-807.
8. Galati G, Sabzevari O, Wilson JX, O'Brien PJ. Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology 2002;177:91-104.
9. Meeran SM, Katiyar SK. Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci 2008;13:2191-202.
10. Ren W, Qiao Z, Wang H, Zhu L, Zhang L. Flavonoids: promising anticancer agents. Med Res Rev 2003;23:519-34.
11. Khantamat O, Wittaya Chaiwangyen MS, Porn-ngarm Limtrakul MS. Screening of flavonoids for their potential Inhibitory effect on p-glycoprotein activity in human cervical carcinoma Kb cells. Chiang Mai Med Bull 2004;43:45-56.
12. Yamashita Y, Kawada S, Fujii N, Nakano H. Induction of mammalian DNA Topoisomerase II dependent DNA cleavage by antitumor antibiotic streptonigrin. Cancer Res 1990;50:5841-4.
13. Webb MR, Ebeler SE. Comparative analysis of Topoisomerase IB inhibition and DNA intercalation by flavonoids and similar compounds: structural determinates of activity. Biochem J 2004;384:527-41.
14. López-Lázaro M, Martín-Cordero C, Toro MV, Ayuso MJ. Flavonoids as DNA Topoisomerase I Poisons. J Enzyme Inhib Med Chem 2006;233:255-64.
15. Constantinou A, Mehta R, Runyan C, Rao K, Vaughan A, Moon R. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J Nat Prod 1995;58:217-25.
16. Orsolic N, Kosalec I, Basic I. Synergystic antitumor effect of polyphenolic components of water soluble derivative of propolis against Ehrlich ascites tumour. Biol Pharm Bull 2005;28:694-700.
17. Benkovic V, Horvat Knezevic A, Brozovic G, Knezevic F, Dikic D, Bevanda M et al. Enhanced antitumor activity of irinotecan combined with propolis and its polyphenolic compounds on Ehrlich ascites tumor in mice. Biomed Pharmacother 2007;61:292-7.
18. Oršolić N, Benković V, Lisičić D, Dikić D, Erhardt J, Horvat Knežević A. Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan. Med Oncol 2009;27:1346-58.
19. Cao S, Durrani FA, Rustum YM. Synergistic antitumor activity of capecitabine in combination with irinotecan. Clin Colorectal Cancer 2005;4:336-43.
20. Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC. Human tumor xenograft models in NCI drug development. In: Teicher B (ed.). Anticancer Development Guide: Preclinical Screening, Clinical Trials and Approval. Humana Press Inc., Totowa, USA, 1997;101-25.
21. Doeing DC, Borowicz J, Crockett ET. Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. BMC Clin Pathol 2003;3:3.
22. Bergman RA, Afifi AK, Heidger PM. Histology. Saunders Publishing, Philadelphia, PA, 1995.
23. Fecchio D, Sirois P, Russo M, Jancar S. Studies on inflammatory response induced by Ehrlich tumor in mice peritoneal cavity. Inflammation 1990;14:125-32.
24. Singh NP, McCoy MT, Tice RR, Schneider LL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;75:184-91.
25. Benković V, Knežević A, Dikić D, Lisičić D, Oršolić N, Bašić I et al. Radioprotective effects of quercetin and ethanolic extract of propolis in gamma-irradiated mice. Arh Hig Rada Toksikol 2009;60:129-38.
26. Kandaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT et al. The antitumor activities of flavonoids. In Vivo 2005;19:895-909.
27. Fresco P, Borges F, Diniz C, Marques MP. New insights on the anticancer properties of dietary polyphenols. Med Res Rev 2006;26:747-66.
28. Liu HL, Jiang WB, Xie MX. Flavonoids: recent advances as anticancer drugs. Recent Pat Anticancer Drug Discov 2010;5:152-64.
29. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001;74:418-25.
30. Orsolić N, Knezević AH, Sver L, Terzić S, Basić I. Immunomodulatory and antimetastatic action of propolis and related polyphenolic compounds. J Ethnopharmacol 2004;94:307-15.
31. Kopjar N, Zeljezić D, Vrdoljak AL, Radić B, Ramić S, Milić M et al. Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers. Basic Clin Pharmacol Toxicol 2007;100:403-13.
32. Bischoff SC. Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care 2008;11:733-40.
33. González-Gallego J, García-Mediavilla MV, Sánchez-Campos S, Tuñón MJ. Fruit polyphenols, immunity and inflammation. Br J Nutr 2010;104:S15-27.
34. Cotelle N. Role of flavonoids in oxidative stress. Curr Top Med Chem 2001;1:569-90.
35. Lee JC, Kim J, Park JK, Chung GH, Jang YS. The antioxidant, rather than prooxidant, activities of quercetin on normal cells: quercetin protects mouse thymocytes from glucose oxidase-mediated apoptosis. Exp Cell Res 2003;291:386-97.
36. Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002;2:103-23.
37. Hartmann JT, Lipp HP. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf 2006;29:209-30.